Symbols / DWTX Stock $1.35 +0.75% Dogwood Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
DWTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Gregory Duncan
Exch · Country NCM · United States
Market Cap 45.09M
Enterprise Value 79.06M
Income -35.51M
Sales —
FCF (ttm) -17.34M
Book/sh 2.52
Cash/sh 0.20
Employees 8
Insider 10d —
IPO Dec 17, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.21
PEG —
P/S —
P/B 0.54
P/C —
EV/EBITDA -2.83
EV/Sales —
Quick Ratio 2.13
Current Ratio 2.76
Debt/Eq 0.22
LT Debt/Eq —
EPS (ttm) -7.13
EPS next Y -6.37
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-03-18
ROA -18.95%
ROE -49.23%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 33.40M
Shs Float 4.80M
Insider Own 75.00%
Instit Own 11.05%
Short Float 0.40%
Short Ratio 0.41
Short Interest 46.58K
52W High 9.50
vs 52W High -85.79%
52W Low 1.28
vs 52W Low 5.30%
Beta 2.07
Impl. Vol. —
Rel Volume 0.98
Avg Volume 81.05K
Volume 79.19K
Target (mean) $14.00
Tgt Median $15.00
Tgt Low $12.00
Tgt High $15.00
# Analysts 3
Recom None
Prev Close $1.34
Price $1.35
Change 0.75%
About

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.00
Mean price target
2. Current target
$1.35
Latest analyst target
3. DCF / Fair value
$-9.34
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.35
Low
$12.00
High
$15.00
Mean
$14.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-27 reit HC Wainwright & Co. Buy → Buy $12
2026-02-20 reit HC Wainwright & Co. Buy → Buy $12
2026-01-30 reit HC Wainwright & Co. Buy → Buy $12
2025-09-30 main HC Wainwright & Co. Buy → Buy $12
2025-04-23 up HC Wainwright & Co. Neutral → Buy $10
News
RSS: Latest DWTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-11-21 SEALBOND LTD Beneficial Owner of more than 10% of a Class of Security — 24,453,588 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
27.97
+128.74%
12.23
+124.48%
5.45
-55.77%
12.32
Research And Development
21.87
+519.28%
3.53
+104.33%
1.73
-78.59%
8.07
Selling General And Administration
6.10
-29.83%
8.70
+133.85%
3.72
-12.41%
4.25
General And Administrative Expense
6.10
-29.83%
8.70
+133.85%
3.72
-12.41%
4.25
Other Gand A
6.10
-29.83%
8.70
+133.85%
3.72
-12.41%
4.25
Total Expenses
27.97
+128.74%
12.23
+124.48%
5.45
-55.77%
12.32
Operating Income
-27.97
-128.74%
-12.23
-124.48%
-5.45
+55.77%
-12.32
Total Operating Income As Reported
-27.97
-128.74%
-12.23
-124.48%
-5.45
+55.77%
-12.32
EBITDA
-27.97
-128.95%
-12.22
-124.26%
-5.45
+55.77%
-12.32
Normalized EBITDA
-21.80
-78.93%
-12.18
-123.69%
-5.45
+55.77%
-12.32
Reconciled Depreciation
0.00
-83.06%
0.01
0.00
—
EBIT
-27.97
-128.74%
-12.23
-124.48%
-5.45
+55.77%
-12.32
Total Unusual Items
-6.16
-19923.93%
-0.03
—
—
Total Unusual Items Excluding Goodwill
-6.16
-19923.93%
-0.03
—
—
Special Income Charges
-6.14
0.00
—
—
Other Special Charges
6.13
—
—
—
Net Income
-34.26
-177.39%
-12.35
-133.19%
-5.30
+56.76%
-12.25
Pretax Income
-34.04
-175.59%
-12.35
-133.20%
-5.30
+56.76%
-12.25
Net Non Operating Interest Income Expense
0.10
+205.15%
-0.09
-161.09%
0.15
+123.64%
0.07
Interest Expense Non Operating
—
0.09
—
—
Net Interest Income
0.10
+205.15%
-0.09
-161.09%
0.15
+123.64%
0.07
Interest Expense
—
0.09
—
—
Interest Income Non Operating
—
—
0.15
+123.64%
0.07
Interest Income
—
—
0.15
+123.64%
0.07
Other Income Expense
-6.16
-19923.93%
-0.03
—
—
Other Non Operating Income Expenses
—
—
—
—
Gain On Sale Of Security
-0.03
+9.33%
-0.03
—
—
Tax Provision
0.22
+44055.47%
-0.00
0.00
0.00
Tax Rate For Calcs
0.00
+512095.12%
0.00
0.00
0.00
Tax Effect Of Unusual Items
-1.29
-103246434.59%
-0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-34.26
-177.39%
-12.35
-133.19%
-5.30
+56.76%
-12.25
Net Income From Continuing Operation Net Minority Interest
-34.26
-177.39%
-12.35
-133.19%
-5.30
+56.76%
-12.25
Net Income From Continuing And Discontinued Operation
-34.26
-177.39%
-12.35
-133.19%
-5.30
+56.76%
-12.25
Net Income Continuous Operations
-34.26
-177.39%
-12.35
-133.19%
-5.30
+56.76%
-12.25
Normalized Income
-29.39
-138.55%
-12.32
-132.61%
-5.30
+56.76%
-12.25
Net Income Common Stockholders
-35.51
-176.08%
-12.86
-142.90%
-5.30
+56.76%
-12.25
Diluted EPS
—
-12.52
-78.86%
-7.00
+74.77%
-27.75
Basic EPS
—
-12.52
-78.86%
-7.00
+74.77%
-27.75
Basic Average Shares
—
1.03
+36.84%
0.75
+69.62%
0.44
Diluted Average Shares
—
1.03
+36.84%
0.75
+69.62%
0.44
Diluted NI Availto Com Stockholders
-35.51
-176.08%
-12.86
-142.90%
-5.30
+56.76%
-12.25
Gain On Sale Of PPE
-0.00
0.00
—
—
Preferred Stock Dividends
1.26
+144.44%
0.51
—
—
Total Other Finance Cost
-0.10
-205.15%
0.09
—
-0.07
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
90.17
-4.39%
94.31
+2164.06%
4.17
Current Assets
8.43
-49.04%
16.54
+297.18%
4.17
Cash Cash Equivalents And Short Term Investments
6.52
-56.06%
14.85
+347.64%
3.32
Cash And Cash Equivalents
6.52
-56.06%
14.85
+347.64%
3.32
Cash Financial
6.52
-56.06%
14.85
+347.64%
3.32
Prepaid Assets
1.90
+13.97%
1.67
+97.47%
0.84
Other Current Assets
0.00
-82.59%
0.03
+686.91%
0.00
Total Non Current Assets
81.74
+5.11%
77.76
0.00
Net PPE
0.19
-19.04%
0.24
0.00
Gross PPE
0.19
-19.57%
0.24
0.00
Accumulated Depreciation
0.00
+100.00%
-0.00
—
Machinery Furniture Equipment
0.01
-30.64%
0.02
—
Construction In Progress
0.02
+4.99%
0.02
—
Other Properties
0.16
-20.74%
0.21
—
Goodwill And Other Intangible Assets
81.39
+4.98%
77.52
0.00
Goodwill
12.40
+4.98%
11.81
0.00
Other Intangible Assets
68.99
+4.98%
65.71
—
Non Current Deferred Assets
0.16
0.00
—
Non Current Prepaid Assets
—
0.02
0.00
Total Liabilities Net Minority Interest
15.27
-49.13%
30.03
+8274.67%
0.36
Current Liabilities
3.06
-3.69%
3.18
+785.89%
0.36
Payables And Accrued Expenses
2.26
-5.53%
2.39
+566.40%
0.36
Payables
0.76
-38.23%
1.23
+1000.68%
0.11
Accounts Payable
0.76
-38.23%
1.23
+1000.68%
0.11
Current Accrued Expenses
1.50
+29.27%
1.16
+369.34%
0.25
Pensionand Other Post Retirement Benefit Plans Current
0.75
+1.06%
0.74
0.00
Current Debt And Capital Lease Obligation
0.06
+14.38%
0.05
—
Current Capital Lease Obligation
0.06
+14.38%
0.05
0.00
Total Non Current Liabilities Net Minority Interest
12.22
-54.51%
26.85
0.00
Long Term Debt And Capital Lease Obligation
0.11
-99.32%
15.54
0.00
Long Term Debt
—
15.38
—
Long Term Capital Lease Obligation
0.11
-31.72%
0.15
0.00
Non Current Deferred Liabilities
12.11
+7.02%
11.31
0.00
Non Current Deferred Taxes Liabilities
12.11
+7.02%
11.31
0.00
Stockholders Equity
74.90
+16.51%
64.28
+1588.54%
3.81
Common Stock Equity
74.90
+839.77%
-10.12
-365.95%
3.81
Capital Stock
0.00
-100.00%
74.41
+96630412.99%
0.00
Common Stock
0.00
+2136.09%
0.00
+72.73%
0.00
Preferred Stock
0.00
-100.00%
74.41
0.00
Share Issued
29.75
+2120.41%
1.34
+72.22%
0.78
Ordinary Shares Number
29.74
+2132.70%
1.33
+72.94%
0.77
Treasury Shares Number
0.01
+0.00%
0.01
+0.00%
0.01
Additional Paid In Capital
183.86
+170.95%
67.86
+3.48%
65.58
Retained Earnings
-108.08
-46.41%
-73.82
-20.09%
-61.47
Gains Losses Not Affecting Retained Earnings
-0.59
+84.80%
-3.86
0.00
Treasury Stock
0.30
+0.00%
0.30
+0.00%
0.30
Other Equity Adjustments
-0.59
+84.80%
-3.86
—
Total Equity Gross Minority Interest
74.90
+16.51%
64.28
+1588.54%
3.81
Total Capitalization
74.90
-5.98%
79.66
+1992.57%
3.81
Working Capital
5.37
-59.81%
13.37
+251.16%
3.81
Invested Capital
74.90
+1324.78%
5.26
+38.08%
3.81
Total Debt
0.16
-98.96%
15.59
0.00
Net Debt
—
0.53
—
Capital Lease Obligations
0.16
-20.52%
0.20
0.00
Net Tangible Assets
-6.49
+50.99%
-13.24
-447.84%
3.81
Tangible Book Value
-6.49
+92.60%
-87.65
-2402.33%
3.81
Interest Payable
0.19
-54.95%
0.42
+121.99%
0.19
Preferred Stock Equity
—
74.41
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-15.62
-77.67%
-8.79
-80.49%
-4.87
+57.53%
-11.47
Cash Flow From Continuing Operating Activities
-15.62
-77.67%
-8.79
-80.49%
-4.87
+57.53%
-11.47
Net Income From Continuing Operations
-34.26
-177.39%
-12.35
-133.19%
-5.30
+56.76%
-12.25
Depreciation Amortization Depletion
0.00
-83.06%
0.01
0.00
—
Depreciation
0.00
-83.06%
0.01
0.00
—
Depreciation And Amortization
0.00
-83.06%
0.01
0.00
—
Other Non Cash Items
18.16
+401.48%
3.62
—
—
Stock Based Compensation
0.36
-25.29%
0.48
-23.22%
0.62
+6.40%
0.58
Provisionand Write Offof Assets
—
—
—
—
Deferred Tax
0.22
+44055.47%
-0.00
0.00
—
Deferred Income Tax
0.22
+44055.47%
-0.00
0.00
—
Operating Gains Losses
0.03
-0.45%
0.03
—
—
Net Foreign Currency Exchange Gain Loss
0.03
-9.33%
0.03
0.00
—
Gain Loss On Sale Of PPE
0.00
0.00
—
—
Change In Working Capital
-0.13
+77.12%
-0.58
-198.94%
-0.19
-198.51%
0.20
Change In Prepaid Assets
-0.21
+58.16%
-0.50
-201.72%
0.49
+14.09%
0.43
Change In Payables And Accrued Expense
0.08
+191.68%
-0.08
+87.94%
-0.68
-194.68%
-0.23
Change In Accrued Expense
0.61
+301.13%
-0.30
-35.34%
-0.22
+50.52%
-0.45
Change In Payable
-0.53
-342.22%
0.22
+147.67%
-0.46
-310.33%
0.22
Change In Account Payable
-0.53
-342.22%
0.22
+147.67%
-0.46
-310.33%
0.22
Investing Cash Flow
0.00
-100.00%
3.76
0.00
—
Cash Flow From Continuing Investing Activities
0.00
-100.00%
3.76
0.00
—
Net Business Purchase And Sale
0.00
-100.00%
3.76
0.00
—
Financing Cash Flow
7.28
-56.39%
16.70
+1344.47%
1.16
-74.25%
4.49
Cash Flow From Continuing Financing Activities
7.28
-56.39%
16.70
+1344.47%
1.16
-74.25%
4.49
Net Issuance Payments Of Debt
3.00
-80.42%
15.32
0.00
—
Issuance Of Debt
3.00
-80.42%
15.32
0.00
—
Long Term Debt Issuance
3.00
-80.42%
15.32
0.00
—
Net Long Term Debt Issuance
3.00
-80.42%
15.32
0.00
—
Net Common Stock Issuance
4.34
+213.98%
1.38
+19.49%
1.16
-74.25%
4.49
Common Stock Payments
0.00
+100.00%
-0.00
0.00
—
Cash Dividends Paid
—
—
—
—
Repurchase Of Capital Stock
0.00
+100.00%
-0.00
0.00
—
Proceeds From Stock Option Exercised
—
—
—
0.00
Net Other Financing Charges
-0.05
—
—
—
Changes In Cash
-8.33
-171.38%
11.68
+414.36%
-3.71
+46.77%
-6.98
Effect Of Exchange Rate Changes
0.01
+107.36%
-0.14
0.00
—
Beginning Cash Position
14.85
+347.64%
3.32
-52.82%
7.03
-49.81%
14.01
End Cash Position
6.52
-56.06%
14.85
+347.64%
3.32
-52.82%
7.03
Free Cash Flow
-15.62
-77.67%
-8.79
-80.49%
-4.87
+57.53%
-11.47
Interest Paid Supplemental Data
—
—
—
—
Common Stock Issuance
4.34
+213.90%
1.38
+19.52%
1.16
-74.25%
4.49
Interest Paid CFF
—
—
—
—
Issuance Of Capital Stock
4.34
+213.90%
1.38
+19.52%
1.16
-74.25%
4.49
Sale Of Business
0.00
-100.00%
3.76
0.00
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category